Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells

Cancer Research

Volumn 65, Issue 6, 2005, Pages 2465-2473

  Mitsutake, Norisato ^a   Knauf, Jeffrey A ^a   Mitsutake, Shin ^a   Mesa Jr , Cleo ^a   Zhang, Lei ^a   Fagin, James A ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; ANEUGEN; B RAF KINASE; CLASTOGEN; CYCLIC AMP; DNA; DOXYCYCLINE; FORSKOLIN; PROTEIN PATCHED; PROTEIN RET; THYROTROPIN; THYROTROPIN RECEPTOR; ISOPROTEIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; CELL LINE; CHROMOSOMAL INSTABILITY; CLONE; CONTROLLED STUDY; DNA SYNTHESIS; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE EXPRESSION; GENOMIC INSTABILITY; MICRONUCLEUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; THYROID CELL; ANIMAL; BIOSYNTHESIS; CELL TRANSFORMATION; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; THYROID GLAND; THYROID TUMOR;

ADENYLATE CYCLASE; ANIMALS; APOPTOSIS; CELL DIFFERENTIATION; CELL GROWTH PROCESSES; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOMAL INSTABILITY; DNA, NEOPLASM; DOXYCYCLINE; MICE; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS B-RAF; RATS; THYROID GLAND; THYROID NEOPLASMS;

EID: 16844367605     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-3314     Document Type: Article

References (46)

1. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
2. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003;63:1454-7.
3. Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003;95:625-7.
4. Soares P, Trovisco V, Rocha AS, et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 2003;22:4578-80.
5. Namba H, Nakashima M, Hayashi T, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 2003;88:4393-7.
6. Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 2003;63:4561-7.
7. Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003;88:5399-404.
8. Fukushima T, Suzuki S, Mashiko M, et al. BRAF mutations in papillary carcinomas of the thyroid. Oncogene 2003;22:6455-7.
9. Kumar R, Angelini S, Czene K, et al. BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clin Cancer Res 2003;9:3362-8.
10. Dhillon AS, Kolch W. Oncogenic B-Raf mutations: crystal clear at last. Cancer Cell 2004;5:303-4.
11. Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116:855-67.
12. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet 2003;33:19-20.
13. Fugazzola L, Pilotti S, Pinchera A, et al. Oncogenic rearrangements of the RET proto-oncogene in papillary thyroid carcinomas from children exposed to the Chernobyl nuclear accident Cancer Res 1995;55:5617-20.
14. Bongarzone I, Fugazzola L, Vigneri P, et al. Age-related activation of the tyrosine kinase receptor protooncogenes RET and NTRK1 in papillary thyroid carcinoma. J Clin Endocrinol Metab 1996;81:2006-9.
15. Klugbauer S, Lengfelder E, Demidchik EP, Rabes HM. High prevalence of RET rearrangement in thyroid tumors of children from Belarus after the Chernobyl reactor accident. Oncogene 1995;11:2459-67.
16. Nikiforov YE, Rowland JM, Bove KE, Monforte-Munoz H, Fagin JA. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res 1997;57:1690-4.
17. Frattini M, Ferrario C, Bressan P, et al. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 2004;23:7436-40.
18. Nikiforov YE. RET/PTC rearrangement in thyroid tumors. Endocr Pathol 2002;13:3-16.
19. Trovisco V, Vieira de Castro I, Soares P, et al. BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol 2004;202:247-51.
20. De Vita G, Zannini M, Cirafici AM, et al. Expression of the RET/PTC1 oncogene impairs the activity of TTF-1 and Pax·8 thyroid transcription factors. Cell Growth Differ 1998;9:97-103.
21. Portella G, Vitagliano D, Borselli C, et al. Human N-ras, TRK-T1, and RET/PTC3 oncogenes, driven by a thyroglobulin promoter, differently affect the expression of differentiation markers and the proliferation of thyroid epithelial cells. Oncol Res 1999;11:421-7.
22. Knauf JA, Kuroda H, Basu S, Fagin JA. RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase. Oncogene 2003;22:4406-12.
23. Shirokawa JM, Elisei R, Knauf JA, et al. Conditional apoptosis induced by oncogenic ras in thyroid cells. Mol Endocrinol 2000;14:1725-38.
24. Puxeddu E, Mitsutake N, Knauf JA, et al. Microsomal prostaglandin E2 synthase-1 is induced by conditional expression of RET/PTC in thyroid PCCL3 cells through the activation of the MEK-ERK pathway. J Biol Chem 2003;278:52131-8.
25. Muller PY, Janovjak H, Miserez AH, Dobbie Z. Processing of gene expression data generated by quantitative real-time RT-PCR Biotechniques 2002;32:1372-4, 6, 8-9.
26. Barnier JV, Papin C, Eychene A, Lecoq O, Calothy G. The mouse B-raf gene encodes multiple protein isoforms with tissue-specific expression. J Biol Chem 1995;270:23381-9.
27. Papin C, Eychene A, Brunet A, et al. B-Raf protein isoforms interact with and phosphorylate Mek-1 on serine residues 218 and 222. Oncogene 1995;10:1647-51.
28. Kerkhoff E, Rapp UR. High-intensity Raf signals convert mitotic cell cycling into cellular growth. Cancer Res 1998;58:1636-40.
29. Saavedra HI, Knauf JA, Shirokawa JM, et al. The RAS oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK pathway. Oncogene 2000;19:3948-54.
30. Kimura T, Van Keymeulen A, Golstein J, Fusco A, Dumont JE, Roger PP. Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models. Endocr Rev 2001;22:631-56.
31. Santoro M, Melillo RM, Grieco M, Berlingieri MT, Vecchio G, Fusco A. The TRK and RET tyrosine kinase oncogenes cooperate with ras in the neoplastic transformation of a rat thyroid epithelial cell line. Cell Growth Differ 1993;4:77-84.
32. Wang J, Knauf JA, Basu S, et al. Conditional expression of RET/PTC induces a weak oncogenic drive in thyroid PCCL3 cells and inhibits thyrotropin action at multiple levels. Mol Endocrinol 2003;17:1425-36.
33. Vanvooren V, Allgeier A, Cosson E, et al. Expression of multiple adenylyl cyclase isoforms in human and dog thyroid. Mol Cell Endocrinol 2000;170:185-96.
34. Lai HL, Yang TH, Messing RO, Ching YH, Lin SC, Chern Y. Protein kinase C inhibits adenylyl cyclase type VI activity during desensitization of the A2a-adenosine receptor-mediated cAMP response. J Biol Chem 1997;272:4970-7.
35. Knauf JA, Ouyang B, Croyle M, Kimura E, Fagin JA. Acute expression of RET/PTC induces isozyme-specific activation and subsequent downregulation of PKCε in PCCL3 thyroid cells. Oncogene 2003;22:6830-8.
36. Tan CM, Kelvin DJ, Litchfield DW, Ferguson SS, Feldman RD. Tyrosine kinase-mediated serine phosphorylation of adenylyl cyclase. Biochemistry 2001;40:1702-9.
37. Depoortere F, Van Keymeulen A, Lukas J, et al. A requirement for cyclin D3-cyclin-dependent kinase (cdk)-4 assembly in the cyclic adenosine monophosphate-dependent proliferation of thyrocytes. J Cell Biol 1998;140:1427-39.
38. Paternot S, Coulonval K, Dumont JE, Roger PP. Cyclic AMP-dependent phosphorylation of cyclin D3-bound CDK4 determines the passage through the cell cycle restriction point in thyroid epithelial cells. J Biol Chem 2003;278:26533-40.
39. Arsenijevic T, Degraef C, Dumont JE, Roger PP, Pirson I. A novel partner for D-type cyclins: protein kinase A-anchoring protein AKAP95. Biochem J 2004;378:673-9.
40. Francis-Lang H, Zannini M, De Felice M, Berlingieri MT, Fusco A, Di Lauro R. Multiple mechanisms of interference between transformation and differentiation in thyroid cells. Mol Cell Biol 1992;12:5793-800.
41. Missero C, Pirro MT, Di Lauro R. Multiple ras downstream pathways mediate functional repression of the homeobox gene product TTF-1. Mol Cell Biol 2000;20:2783-93.
42. Miller BM, Nusse M. Analysis of micronuclei induced by 2-chlorobenzylidene malonitrile (CS) using fluorescence in situ hybridization with telomeric and centromeric DNA probes, and flow cytometry. Mutagenesis 1993;8:35-41.
43. Muller WU, Nusse M, Miller BM, Slavotinek A, Viaggi S, Streffer C. Micronuclei: a biological indicator of radiation damage. Mutat Res 1996;366:163-9.
44. Zecevic M, Catling AD, Eblen ST, et al. Active MAP kinase in mitosis: localization at kinetochores and association with the motor protein CENP-E. J Cell Biol 1998;142:1547-58.
45. Shapiro PS, Vaisberg E, Hunt AJ, et al. Activation of the MKK/ERK pathway during somatic cell mitosis: direct interactions of active ERK with kinetochores and regulation of the mitotic 3F3/2 phosphoantigen. J Cell Biol 1998;142:1533-45.
46. Saavedra HI, Fukasawa K, Conn CW, Stambrook PJ. MAPK mediates RAS-induced chromosome instability. J Biol Chem 1999;274:38083-90.